Pfizer terminates global license deal for Theravance's preclinical JAK inhibitor

Theravance Biopharma, Inc.

Termination effective Oct 7, 2023; Pfizer gave notice June 9, 2023.
Agreement covered preclinical skin-selective, locally acting pan-JAK inhibitor program.
No reason for termination or financial impact disclosed by Theravance.
Theravance regains rights to the program subject to wind-down obligations.

item 1.02

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Theravance Biopharma, Inc. terminated Pfizer Agreement with Pfizer Inc. (effective 2023-10-07).

Action: termination
Agreement: license
Counterparty: Pfizer Inc.
Effective: 2023-10-07

Exact text from the filing

On June 9 , 2023, the Company received notice from Pfizer terminating the Pfizer Agreement, effective as of October 7, 2023.

View on SEC.gov

Browse all material agreements →

Theravance Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-069993

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.